Pulmonary Pathologic Manifestations of Anti-Alanyl-tRNA Synthetase (Anti-PL-12)-Related Inflammatory Myopathy.
Lung involvement, mostly in the form of ILD, is common in ARS, affecting up to 90% of patients with anti-PL-12 ARS. (2-6) Most patients present with progressive dyspnea and cough. (5,6) Although radiographic findings, including bibasilar fibrosis, ground-glass opacities, interlobular reticulation, and traction bronchiectasis, have been described, the corresponding histopathology has been poorly documented. (6)
Here, we present the clinical and pathologic findings in 12 patients with anti-PL-12 antibodies, to our knowledge, the largest and most comprehensive study to date of pulmonary histopathologic features in anti-PL-12 ARS.
MATERIALS AND METHODS
The University of Pittsburgh's Idiopathic Inflammatory Myopathy registry was searched for patients who, at the time of their initial clinical evaluation, were found to have anti-PL-12 antibodies. AntiPL-12 was identified by radiolabeled protein immunoprecipitation, with positive results confirmed by RNA immunoprecipitation, as previously described. (7)
Clinical features were extracted from this myositis registry, which encompasses more than 3 decades of prospective data and serum collected on consecutive outpatients and inpatients with myositis evaluated at the University of Pittsburgh (Pittsburgh, Pennsylvania). The extracted database was complemented by retrospective review of the electronic medical record. Patients possessing antiPL-12 autoantibodies who were initially seen between January 1985 and December 2012 were included, regardless of their connective tissue disease (CTD) diagnosis. Patients with myositis met the diagnostic criteria of Bohan and Peter, (8) whereas the diagnoses of systemic sclerosis, Sjogren syndrome, undifferentiated CTD (UCTD), or other overlapping rheumatic syndromes were made clinically by experienced rheumatologists.
All variables (clinical, laboratory, radiographic, and pathologic) and organ system definitions were well defined and standardized in this registry. Organ involvement was defined as follows: (1) vascular, the presence of Raynaud phenomenon, digital pitting scars, ulcers and gangrene, or abnormal nailfold capillaries; (2) cutaneous, characteristic rashes of DM or sclerodactyly; (3) joints, objective joint swelling and tenderness; (4) muscle, objective, proximal muscle weakness, in addition to any one of the following: elevated serum creatine kinase, myopathic electromyogram, or myositis on muscle biopsy; (5) gastrointestinal, proximal or distal, esophageal dysmotility or small/large bowel involvement; (6) pulmonary, fibrosis on chest radiograph or high-resolution chest computed tomography; and (7) primary pulmonary artery hypertension, mean pulmonary artery pressure more than 25 mm Hg on cardiac catheterization or systolic pressure more than 40 mm Hg estimated by echocardiography in the absence of significant pulmonary and/or cardiac disease causing secondary pulmonary artery hypertension. Interpretations of chest computed tomographies were performed by thoracic radiologists at our institution.
Only patients for whom histology slides of lung tissue were available for review were included in the study. An average number of 12 slides stained with hematoxylin-eosin were available for study (median, 7; range, 2-52). The histopathologic pattern of lung involvement was classified according to the American Thoracic Society/European Respiratory Society consensus classification of idiopathic interstitial pneumonias. (9,10) A clinical diagnosis of ILD required restrictive physiology on pulmonary function testing and abnormal radiologic findings by high-resolution chest computed tomography characterized by at least one of the following: reticulation, traction bronchiectasis, honeycomb change, or ground-glass opacities.
Specimens from 12 patients were available for study; 10 patients had surgical lung biopsies (1 underwent bilateral lung transplantation 3 years later; 1 underwent transbronchial biopsy 5 years later; both were also available for review), and 2 patients underwent single and double lung transplantation, respectively.
The clinical features of the 12 patients with anti-PL-12 autoantibodies are shown in Table 1. The patients' median age was 52 years (range, 17-64), with 9 woman and 3 men. Most patients presented with dyspnea (9 of 75; 67%) as their initial symptom. Four patients carried a diagnosis of PM, 5 had UCTD, 2 had systemic sclerosis, and 1 had Sjogren syndrome. The most common ARS features, other than dyspnea, were erythematous skin rashes in 5 of 12 patients (42%), sclerodactyly in 2 of 12 patients (17%), Raynaud phenomenon in 7 of 12 patients (58%), and fever in 5 of 12 patients (42%). Nearly all patients had radiographic features of usual interstitial pneumonia (UIP) on high-resolution chest computed tomography with bibasilar reticular infiltrates, traction bronchiectasis, and subpleural honeycomb change. One patient was deceased, but all living patients had active disease, mostly manifested as ILD. Three patients had undergone therapeutic lung transplant procedures during their follow-up period; all are alive, having survived a mean of 7 years after transplant.
Histopathologic and radiographic features are summarized in Table 2. Usual interstitial pneumonia was the most common pattern of lung involvement and was noted in 8 of 12 patients (67%) (Figure 1, A and B). Findings included typical, peripherally accentuated fibrosis of lung lobules with honeycomb changes and fibroblastic foci. Interstitial lymphoplasmacytic inflammation and lymphoid aggregates, with or without germinal centers, were seen in 8 of 12 patients (67%) (Figure 1, C). Two of 12 patients (17%) showed nonspecific interstitial pneumonia (NSIP) as the predominant finding (Figure 1, D). One of those patients had superimposed, presumably infectious, bronchopneumonia. Organizing pneumonia was the predominant pattern of lung disease in 2 of 12 patients (17%) (Figure 2, A), and a focal secondary finding in one patient with UIP and one patient with NSIP. Three of 12 cases (25%) showed a few scattered, nonnecrotizing granulomas (Figure 2, B): 1 with accompanying, presumably infectious, acute bronchitis, and another with features of aspiration. In the third case, granulomas were superimposed on UIP and were of uncertain etiology. A few scattered eosinophils were present in 10 of the 12 patients (83%), appearing prominently in one NSIP biopsy (Figure 2, C) and one patient with UIP and eosinophilic pleuritis. A pulmonary vasculopathy was apparent in 3 patients. In 2 cases, it was characterized by intimal fibrosis and medial hypertrophy of small- to medium-size arteries. In the third case, scattered small arterioles showed concentric muscular hypertrophy (Figure 2, D). Pertinent negative findings were the absence of vasculitis, necrotizing granulomas, amyloid deposits, and acute pleuritis in all cases.
Interstitial lung disease is a common feature in IIM. The reported incidence in DM and PM ranges from 20% to 65%, depending on the criteria used. (11) Nonspecific interstitial pneumonia is 4 times more common than UIP in patients with PM, whereas the difference is less than 2-fold in patients with DM, demonstrating the heterogeneity among patients with IIM in the degree and pattern of lung involvement. (11) Historically, the pattern of disease predicts prognosis: organizing pneumonia offers a better prognosis than UIP does, whereas diffuse alveolar damage portends a particularly poor prognosis. (12)
Herein, we describe the histopathologic features of lung involvement in 12 cases of anti-PL-12 ARS, a distinct subset of IIM, although anti-PL-12 can be seen in clinical association with other CTD or UCTD. Our study provides 2 main findings: (1) there are no pathognomonic features that would allow for a definitive diagnosis of anti-PL-12 ARS based on the histopathologic features alone, and (2) UIP is the most common form of ILD found in this autoantibody cohort.
As noted by other authors, patients with autoimmune disease do not have histologically distinct lung biopsies of their ILD. However, according to Song et al, (13) lymphoid aggregates and subjective, highly cellular biopsies are more often seen in this subgroup. Our cohort of patients with anti-PL-12 ARS mirrors their experience, with more than one-half of patients having a noticeable increase in lymphoid aggregates in their biopsies. Fibroblastic foci were not prominent in our cases, in keeping with results by Enomoto et al (14) in their comparison of idiopathic UIP with CTD-related UIP.
Three of our 8 UIP specimens (38%) showed large areas resembling NSIP. Finding NSIP in patients with diffuse ILD usually raises the possibility of underlying, possibly occult, CTD because NSIP is a more commonly found pattern in CTD-related ILD. Several small series have identified NSIP as the most common pattern in patients with myositis-associated ILD. (15) The prevalence of antisynthetase antibodies in these cohorts is either not known or not correlated with the histopathologic pattern. Heterogeneous ILD with an NSIP pattern has also been described in patients with idiopathic pulmonary fibrosis. (16) At least a subset of NSIP cases appears to have the biologic potential to progress to a more advanced pattern of fibrosis. (17)
Nonnecrotizing granulomas were seen in 3 patients: 1 patient carried a diagnosis of Sjogren syndrome, the other 2 met criteria for UCTD, including 1 with elements of rheumatoid arthritis. Although granulomas have been associated with systemic conditions, such as rheumatoid arthritis, inflammatory bowel disease, and hypersensitivity reactions, they may also occur in the setting of infection, aspiration, tissue breakdown, or with certain pneumotoxic drugs. Their presence is not specific enough to strongly suggest lung involvement by ARS.
Histologic evidence of a vasculopathy was observed in 3 of 12 patients (25%) in this cohort. In 2 patients, this finding correlated with increased mean pulmonary artery pressures of 48 and 27 mm Hg, respectively, as determined by right heart catheterization. The third patient had no evidence of pulmonary hypertension by echocardiography. Pulmonary hypertension is a known complication of ARS. Kalluri et al (5) observed pulmonary hypertension, inferred by means of echocardiography, in 9 of 31 patients (29%) possessing antiPL-12 antibodies.
Table 3 summarizes the pulmonary histopathology of 46 anti-PL-12 cases in the English literature to date. Although the nomenclature is not uniform in these reports, about twothirds of patients seem to have some form of cellular and/or fibrosing ILD. Follow-up was not available for many cases. The existing literature and our cohort confirm that diffuse alveolar damage is not only uncommon in IIM, in general, but also in anti-PL-12 ARS specifically. (18,19) The only patient with diffuse alveolar damage reported in the literature also showed capillaritis and was found to have improved on glucocorticoids 8 months after the episode. One patient who died rapidly of respiratory failure may have had an acute lung injury resembling diffuse alveolar damage. (3)
Distinguishing ILD arising in the setting of ARS from idiopathic variants of ILD is important because recent data show that survival by patients with myositis-associated UIP is better than a matched cohort of patients with idiopathic pulmonary fibrosis. (20) Even within the group of ARS, patients with anti-Jo-1 autoantibodies seem to fare better than do those with other anti-tRNA synthetase autoantibodies, such as anti-PL-12, predominantly because of worse pulmonary outcomes. (7) Thus, considering an ARS in the setting of isolated ILD is valuable because lung disease is the presenting feature in a significant number of such patients. (5) In rare cases, antisynthetase autoantibodies coexist with other autoantibodies, especially Sjogren syndrome-associated antibody anti-SSA. The presence of anti-SSA in patients with ARS may be associated with worse pulmonary outcomes. (4,5,21) Moreover, ARS could be considered and serologically assayed, even in patients with an established autoimmune disease other than myositis.
This study has limitations. We are a tertiary referral center for ILD and rheumatic diseases, as well as a lung transplant center. Our patient cohort may be skewed toward late-stage and progressive lung diseases, such as UIP. However, most of the patients in this study lived close to our center and were followed by rheumatologists within our medical center before referral for lung transplantation. Although UIP representing idiopathic pulmonary fibrosis in patients older than 50 years cannot be excluded with absolute certainty, we believe that the patients in this series most likely suffered from lung involvement by ARS rather than from idiopathic disease because of the high prevalence of ILD in patients with ARS. Furthermore, our patients often experienced the onset of respiratory symptoms long before the diagnosis of ARS and lung biopsy. (7) Two of our patients showed histopathologic features of NSIP in biopsy material. We cannot exclude that these patients were inadequately sampled, especially because the radiologic diagnosis of UIP has high predictive value. (22) However, both biopsies were taken from the lower lobe, making missing UIP less likely if it were present. Finally, a limitation of this study, as seen with any study of this kind, is the lack of an age-matched comparison group showing idiopathic disease.
In summary, there are no pathognomonic histopathologic features to distinguish anti-PL-12 ARS-related lung disease from idiopathic variants of diffuse ILD. Clinical features of mechanic's hands, Raynaud phenomenon, arthritis, and fever should prompt pathologists to suggest involvement by ARS. Because the prognosis of IIM-associated UIP appears to be better than that of idiopathic UIP treated with systemic immunosuppressive therapy, considering the possibility of lung involvement by ARS is important.
(1.) Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007;19(6):523-529.
(2.) Takahashi T, Wada I, Ohtsuka Y, Munakata M, Homma Y, Kuroki Y. Autoantibody to alanyl-tRNA synthetase in patients with idiopathic pulmonary fibrosis. Respirology. 2007;12(5):642-653.
(3.) Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996;26(1):459-467.
(4.) Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med. 1990;88(3):241-251.
(5.) Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest. 2009;135(6): 1550-1556.
(6.) Hervier B, Wallaert B, Hachulla E, et al. Clinical manifestations of antisynthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford). 2010; 49(5):972-976.
(7.) Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNAsynthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73(1):227-232.
(8.) Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-407.
(9.) American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias [adopted by the ATS board of directors June 2001 and by the ERS executive committee, June 2001]. Am J Respir Crit Care Med. 2002;165(2):277-304.
(10.) Travis WD, Costabel U, Hansell DM, et al; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/ European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am i Respir Crit Care Med. 2013;188(6):733-748.
(11.) Fujisawa T, Suda T, Nakamura Y, et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. i Rheumatol. 2005;32(1):58-64.
(12.) Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis. 1990;141(3):727-733.
(13.) Song JW, Do K-H, Kim M-Y, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest. 2009;136(1):23-30.
(14.) Enomoto N, Suda T, Kato M, et al. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest. 2006;130(1):22-29.
(15.) Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138(6):1464-1474.
(16.) Katzenstein A, Zisman D, Litzky L, Nguyen BT, Kotloff RM. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am i Surg Pathol. 2002;26(12):1567-1577.
(17.) Schneider F, Hwang D, Gibson K, Yousem S. Nonspecific interstitial pneumonia: a study of 6 patients with progressive disease. Am i Surg Pathol. 2012;36(1):89-93.
(18.) Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136(5):1341-1347.
(19.) Lee CS, Chen TL, Tzen CY, et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol. 2002;21(5):391-396.
(20.) McBurney C, Aggarwal R, Gibson K, et al. Myositis-associated usual interstitial pneumonia has better survival than idiopathic pulmonary fibrosis [published online ahead of print January 12, 2017]. Rheumatology (Oxford). 2017;56(3):384-389. doi: 10.1093/rheumatology/kew426.
(21.) Prestridge A, Morgan G, Ferguson L, Huang CC, Pachman LM. Pulmonary function tests in idiopathic inflammatory myopathy: association with clinical parameters in children. Arthritis Care Res (Hoboken). 2013;65(9):1424-1431.
(22.) Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
(23.) Kummerfeldt CE, Huggins JT, Riemer EC, Ravenel JG, Whelan TP, Sahn SA. Pulmonary capillaritis in a patient with moderately positive anti-PL-12 antibodies. Int J Rheum Dis. 2013;16(2):233-234.
(24.) Handa T, Nagai S, Kawabata D, et al. Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med. 2005;44(4):319-325.
(25.) Koreeda Y, Higashimoto I, Yamamoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med. 2010;49(5):361-369.
(26.) Marie I, Josse S, Decaux O, et al. Outcome of anti-PL12 positive patients with antisynthetase syndrome. Presse Med. 2013;42(6, pt 1):e153-158.
(27.) Johnson C, Connors GR, Oaks J, et al. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med. 2014;108(10):1542-1548.
Frank Schneider, MD; Samuel A. Yousem, MD; Chester V. Oddis, MD; Rohit Aggarwal, MD
Accepted for publication April 11, 2017.
Published as an Early Online Release October 2, 2017.
From the Department of Pathology, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr Schneider is now with the Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.
The authors have no relevant financial interest in the products or companies described in this article.
Reprints: Frank Schneider, MD, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, 1364 Rd NE, Atlanta, GA 30322 (email: firstname.lastname@example.org).
Caption: Figure 1. Histopathologic features of anti-PL-12 antisynthetase syndrome: usual interstitial pneumonia pattern (A and B), lymphoplasmacytic interstitial inflammation with lymphoid aggregates (C), and nonspecific interstitial pneumonia pattern (D) (hematoxylin- eosin, original magnifications X20 [A], X40 [B and D], and X100 [C]).
Caption: Figure 2. Histopathologic features of anti-PL-12 antisynthetase syndrome: organizing pneumonia (A), nonnecrotizing granulomas (arrow) (B), interstitial eosinophils (C), and vasculopathy involving an arteriole (D) (hematoxylin-eosin, original magnifications X100 [A and B] and X200 [C and D]).
Table 1. Clinical Features of Patients With Anti-PL-12 Autoantibodies (a) Case, Age, (b) Presenting Skin No. y/Sex Symptom Myositis Disease Raynaud Arth- ritis 1 46/F Dyspnea - - - - 2 52/F Dyspnea + + 3 17/F Raynaud + - + + 4 57/F Dyspnea + + + 5 48/F Dyspnea - + - - 6 47/M Dyspnea + + - - 7 64/F Dyspnea - SD + + 8 59/F Dyspnea - - + - 9 64/M Fever - SD + + 10 35/F Dyspnea - + + - 11 60/M Fever + - - - 12 38/F Dyspnea + - - - Case, Mech- Clinical No. anic's Dysphagia Fever Diagnosis Follow-up Hands (c) 1 - - - Sjogren Alive, 12 y 2 + UCTD Alive, lung transplant, 18-y follow-up, 7 y after transplant 3 + - - PM Alive, 7 y 4 UCTD Alive, lung transplant, 10-y follow-up, 5 y after transplant 5 - - - UCTD Alive, 8 y 6 - - + PM Dead, unknown 7 - + + Overlap RA Alive, 15 y and SSc 8 - - - UCTD Alive, lung transplant, 18-y follow-up, 11 y after transplant 9 - - + SSc Alive, 9 y 10 - - - UCTD Alive, 13 y 11 + - + PM Alive, 6 y 12 - - + PM Alive, 20 y Abbreviations: PM, polymyositis;RA, rheumatoid arthritis; SD, sclerodactyly;SSc, systemic sclerosis;UCTD, undifferentiated connective tissue disease. (a) +, present;-, absent. (b) Age at time of (first) tissue sampling. (c) Underlying systemic disease. Table 2. Radiographic and Histopathologic Features of Patients With Anti-PL-12 Autoantibodies Case, Radiologic Type of Lobes No. Diagnosis Biopsy (Slides) (a) 1 UIP 1. SLB 1. 1 (3) 2. Tbbx (+5 y) 2. 1 (1) 2 UIP BLT 5 (52) 3 Subpleural fibrosis, SLB 2 (8) Br'ectasis, and consolidation 4 UIP 1. SLB 5 (30) 2. BLT (+3 y) 5 UIP SLB 2 (12) 6 UIP SLB 1 (6) 7 UIP SLB 2 (4) 8 UIP SLT 2 (11) 9 UIP SLB 1 (2) 10 UIP SLB 1 (4) 11 UIP SLB 1 (6) 12 UIP SLB 2 (10) Case, Main Pattern of Secondary Histopathologic No. Lung Disease Features 1 1. OP 1. Grocott stains negative 2. Acute and 2. Poorly formed nonnecrotizing granulomas; chronic Grocott stain negative bronchitis 2 UIP LPI, LA, few eosinophils, minimal vasculopathy 3 OP Few plasma cells, few eosinophils 4 1. UIP 1. NSIP-like areas, numerous FF, LPI, LA, few eosinophils 2. UIP 2. Widespread NSIP-like areas, multiple small calcifications, rare nonnecrotizing granulomas with giant cells associated with airways 5 UIP LPI, LA, few eosinophils, mild vasculopathy affecting small arterioles 6 NSIP Acute bronchopneumonia, mucoid impaction 7 UIP LA, eosinophilic pleuritis 8 UIP Rare stellate airway-centered scars, few eosinophils 9 NSIP OP, moderate No. of eosinophils, vasculopathy 10 UIP NSIP-like areas, LPI, rare nonnecrotizing granulomas, LA, few eosinophils 11 UIP LA, focal OP, moderate No. of eosinophils, pleuritis 12 UIP LA, moderate eosinophils, vasculopathy, pleuritis Abbreviations: BLT, bilateral lung transplant;Br'ectasis, bronchiectasis;FF, fibroblastic foci;LA, lymphoid aggregates with or without germinal centers;LPI, lymphoplasmacytic inflammatory infiltrates; NSIP, nonspecific interstitial pneumonia;OP, organizing pneumonia;SLB, surgical lung wedge biopsy;SLT, single lung transplant;Tbbx, transbronchial biopsy;UIP, usual interstitial pneumonia. (a) No. of lobes sampled (No. of slides available for study [hematoxylin-eosin]). Table 3. Review of Histopathologic Findings Reported for Anti-PL-12 Antisynthetase Syndrome Patients Source, y Age, y/Sex Kummerfeldt et al, (23) 2013 32/F Handa et al, (24) 2005 44/M Koreeda et al, (25) 2010 61/F Friedman et al, (3) 1996 26/F Friedman et al, (3) 1996 38/F Friedman et al, (3) 1996 47/M Hervier et al, (6) 2010 7 pts Targoff et al, (4) 1990 38/F Targoff et al, (4) 1990 64/M Targoff et al, (4) 1990 53/F Targoff et al, (4) 1990 56/F Takahashi et al, (2) 2007 21 pts (14 F, 7 M); mean age, 59 y Kalluri et al, (5) 2009 12 pts (11 F, 1 M), median age, 52 y Marie et al, (26) 2013 NR Johnson et al, (27) 2014 5 pts (4 F, 1 M), median age, 50 y Source, y Clinical Features Kummerfeldt et al, (23) 2013 Dyspnea, restrictive PFTs Handa et al, (24) 2005 Mechanic's hands, restrictive PFTs, PH Koreeda et al, (25) 2010 PM, also Jo-1 antibodies Friedman et al, (3) 1996 Respiratory failure requiring MV Friedman et al, (3) 1996 Fever, cutaneous vasculitis, Raynaud Friedman et al, (3) 1996 Cough Hervier et al, (6) 2010 Not apparent from data reported Targoff et al, (4) 1990 Cough, chest pain, dyspnea Targoff et al, (4) 1990 PM/DM, Raynaud, heliotrope rash Targoff et al, (4) 1990 PM/DM, synovitis, fever, rash, Raynaud Targoff et al, (4) 1990 PM/DM, arthralgia, rash, dyspnea Takahashi et al, (2) 2007 All IPF Kalluri et al, (5) 2009 9 pts with PM/DM, 1 pt with PM/RA, (a) 2 pts with UCTD Marie et al, (26) 2013 NR Johnson et al, (27) 2014 3 pts with PM, 2 pts with overlap syndrome Source, y Radiologic Features Kummerfeldt et al, (23) 2013 Ill-defined, coalescent peripheral nodular densities at lung bases Handa et al, (24) 2005 Bilateral basal reticular shadows Koreeda et al, (25) 2010 GGO and TB without HC with basilar and BVB predominance Friedman et al, (3) 1996 NR Friedman et al, (3) 1996 NR Friedman et al, (3) 1996 NR Hervier et al, (6) 2010 Not apparent from data reported Targoff et al, (4) 1990 Interstitial infiltrates Targoff et al, (4) 1990 Bibasilar infiltrates Targoff et al, (4) 1990 Bilateral infiltrates Targoff et al, (4) 1990 Bibasilar infiltrates Takahashi et al, (2) 2007 NR Kalluri et al, (5) 2009 5 pts with UIP pattern 6 with NSIP pattern, 1 pt NA Marie et al, (26) 2013 NSIP pattern Johnson et al, (27) 2014 Reported mean CT scores showing moderate fibrosis and moderate ground glass Type of Biopsy Histopathologic Features Follow-up SLB DAD with capillaritis CS, Rituximab, MMF; symptomatic improvement at 8 mo SLB Cellular and fibrosing CS, azathioprine, NSIP and vasculopathy sildenafil; alive with disease at 7 y; undergoing lung transplant evaluation SLB Cellular and fibrosing CS; alive at 26 mo NSIP SLB Acute and chronic Died within 2 wk of interstitial diagnosis inflammation Tbbx Focal interstitial Slowly progressive inflammation and disease despite bronchitis immunosuppression;died after 3 y SLB Diffuse Stable lung disease at 1 lymphoplasmacytic y without treatment infiltrates with Las and interstitial fibrosis 2 SLB, 5 Tbbx Mild interstitial Not apparent from data fibrosis in 3 pts; reported alveolitis in 4 pts Tbbx Interstitial NR lymphoplasmacytic pneumonia Tbbx Pulmonary fibrosis Muscle improved on CS;ILD progressive, dead in 3 y Tbbx Interstitial pneumonitis CS, azathioprine, joints with desquamation improved;continued dyspnea Tbbx Chronic interstitial Alive at 2 y, then lost inflammation and to follow-up fibrosis SLB or PME Reported to correlate NR with the diagnosis of IPF 11 pts SLB, 1 5 pts UIP, 2 pts NSIP, CS, azathioprine;no pt Tbbx (a) 5 pts OP (a) follow-up reported Tbbx Consistent with NSIP NR SLB 3 pts with UIP, 1 pt NR with NSIP, 1 pt with OP Abbreviations: BVB, bronchovascular bundle;CS, corticosteroids;CT, computed tomography;DAD, diffuse alveolar damage;DM, dermatomyositis; GGO, ground-glass opacities;HC, honeycomb change;ILD, interstitial lung disease;IPF, idiopathic pulmonary fibrosis;LAs, lymphoid aggregate; MMF, mycophenolate mofetil;MV, mechanical ventilation;NA, data not available to authors;NR, not reported;NSIP, nonspecific interstitial pneumonia;OP, organizing pneumonia;PFTs, pulmonary function tests;PH, pulmonary hypertension;PM, polymyositis;PME, postmortem examination;pt, patient;pts, patients;RA, rheumatoid arthritis; SLB, surgical lung biopsy;TB, traction bronchiectasis;Tbbx, transbronchial biopsy; UCTD, undifferentiated connective tissue disease;UIP, usual interstitial pneumonia. (a) One patient having undergone transbronchial biopsy had polymyositis with RA and showed organizing pneumonia.